Immunic to showcase phase 2 long-term MS disability data at MSToronto2026

Immunic's Caliper open-label extension data show vidofludimus calcium's disability benefits persisted long-term in progressive MS patients.

• Long-term disability benefit maintained: Immunic's Phase 2 Caliper open-label extension shows disability trends from the double-blind period held up over longer follow-up in progressive MS patients.
• Key endpoints favor the drug: Analyses of 24-week confirmed disability worsening and 24-week confirmed disability improvement both showed favorable long-term results for vidofludimus calcium.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.